nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Urinary hesitation—Fludarabine—lymphatic system cancer	0.0355	0.0355	CcSEcCtD
Dicyclomine—Thrombosis—Mechlorethamine—lymphatic system cancer	0.0317	0.0317	CcSEcCtD
Dicyclomine—Speech impairment NOS—Methotrexate—lymphatic system cancer	0.0198	0.0198	CcSEcCtD
Dicyclomine—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.0188	0.0188	CcSEcCtD
Dicyclomine—Numbness—Fludarabine—lymphatic system cancer	0.0175	0.0175	CcSEcCtD
Dicyclomine—Sensory loss—Fludarabine—lymphatic system cancer	0.0168	0.0168	CcSEcCtD
Dicyclomine—Thrombosis—Carmustine—lymphatic system cancer	0.0132	0.0132	CcSEcCtD
Dicyclomine—Paralysis—Vincristine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Dicyclomine—Necrosis—Carmustine—lymphatic system cancer	0.0119	0.0119	CcSEcCtD
Dicyclomine—Necrosis—Mitoxantrone—lymphatic system cancer	0.011	0.011	CcSEcCtD
Dicyclomine—Speech disorder—Carmustine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Dicyclomine—Numbness—Vincristine—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Dicyclomine—Sensory loss—Vincristine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Dicyclomine—Injection site reaction—Carmustine—lymphatic system cancer	0.00926	0.00926	CcSEcCtD
Dicyclomine—Disorientation—Bleomycin—lymphatic system cancer	0.00865	0.00865	CcSEcCtD
Dicyclomine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00801	0.00801	CcSEcCtD
Dicyclomine—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00781	0.00781	CcSEcCtD
Dicyclomine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00764	0.00764	CcSEcCtD
Dicyclomine—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00727	0.00727	CcSEcCtD
Dicyclomine—Amnesia—Carmustine—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Dicyclomine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00696	0.00696	CcSEcCtD
Dicyclomine—Diplopia—Carmustine—lymphatic system cancer	0.00676	0.00676	CcSEcCtD
Dicyclomine—Agitation—Teniposide—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Dicyclomine—Face oedema—Carmustine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Dicyclomine—Hypertension—Teniposide—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Dicyclomine—Paralysis—Methotrexate—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Dicyclomine—Urinary retention—Vincristine—lymphatic system cancer	0.00613	0.00613	CcSEcCtD
Dicyclomine—Muscular weakness—Carmustine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Dicyclomine—Confusional state—Teniposide—lymphatic system cancer	0.00595	0.00595	CcSEcCtD
Dicyclomine—Oedema—Teniposide—lymphatic system cancer	0.00591	0.00591	CcSEcCtD
Dicyclomine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Dicyclomine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Dicyclomine—Agitation—Fludarabine—lymphatic system cancer	0.00584	0.00584	CcSEcCtD
Dicyclomine—Tachycardia—Teniposide—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Dicyclomine—Malaise—Fludarabine—lymphatic system cancer	0.00573	0.00573	CcSEcCtD
Dicyclomine—Muscular weakness—Vincristine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Dicyclomine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00567	0.00567	CcSEcCtD
Dicyclomine—Anorexia—Teniposide—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Dicyclomine—Necrosis—Methotrexate—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Dicyclomine—Discomfort—Fludarabine—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Dicyclomine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Dicyclomine—Dyspnoea—Teniposide—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Dicyclomine—Confusional state—Fludarabine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Dicyclomine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Dicyclomine—Oedema—Fludarabine—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Dicyclomine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Dicyclomine—Decreased appetite—Teniposide—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Dicyclomine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Dicyclomine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Dicyclomine—Apnoea—Methotrexate—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Dicyclomine—Rash—Mechlorethamine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Dicyclomine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Dicyclomine—Speech disorder—Methotrexate—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Dicyclomine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.005	0.005	CcSEcCtD
Dicyclomine—Anorexia—Fludarabine—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Dicyclomine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Dicyclomine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00484	0.00484	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Dicyclomine—Nausea—Mechlorethamine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Dicyclomine—Urticaria—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Dicyclomine—Abdominal pain—Teniposide—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Dicyclomine—Erythema—Bleomycin—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Dicyclomine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Dicyclomine—Hallucination—Carmustine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Dicyclomine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Dicyclomine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Dicyclomine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Dicyclomine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Dicyclomine—Fatigue—Fludarabine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Dicyclomine—Hallucination—Vincristine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dicyclomine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dicyclomine—Constipation—Fludarabine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dicyclomine—Pain—Fludarabine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Dicyclomine—Eye disorder—Carmustine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Dicyclomine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Dicyclomine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Dicyclomine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Dicyclomine—Asthenia—Teniposide—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Dicyclomine—Malaise—Bleomycin—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Dicyclomine—Pruritus—Teniposide—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Dicyclomine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Dicyclomine—Mental disorder—Carmustine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Dicyclomine—Erythema—Carmustine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Dicyclomine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Dicyclomine—Discomfort—Bleomycin—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Dicyclomine—Mental disorder—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Dicyclomine—Confusional state—Bleomycin—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Dicyclomine—Vision blurred—Carmustine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Dicyclomine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Dicyclomine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Dicyclomine—Oedema—Bleomycin—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Dicyclomine—Erythema—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Dicyclomine—Vomiting—Teniposide—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Dicyclomine—Agitation—Carmustine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Dicyclomine—Asthenia—Fludarabine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Dicyclomine—Rash—Teniposide—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Dicyclomine—Dermatitis—Teniposide—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Dicyclomine—Headache—Teniposide—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Dicyclomine—Pruritus—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Dicyclomine—Anorexia—Bleomycin—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Dicyclomine—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Dicyclomine—Agitation—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Dicyclomine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Dicyclomine—Hypertension—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Dicyclomine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Dicyclomine—Nausea—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Dicyclomine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Dicyclomine—Malaise—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Dicyclomine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Dicyclomine—Hypertension—Vincristine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Dicyclomine—Confusional state—Carmustine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Dicyclomine—Oedema—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Dicyclomine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Dicyclomine—Vomiting—Fludarabine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Dicyclomine—Rash—Fludarabine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Dicyclomine—Dermatitis—Fludarabine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Dicyclomine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Dicyclomine—Pain—Bleomycin—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Dicyclomine—Headache—Fludarabine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Dicyclomine—Tachycardia—Carmustine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Dicyclomine—Lethargy—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Dicyclomine—Discomfort—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Dicyclomine—Oedema—Vincristine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Dicyclomine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Dicyclomine—Anorexia—Carmustine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Dicyclomine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Dicyclomine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Dicyclomine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Dicyclomine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Dicyclomine—Oedema—Mitoxantrone—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Dicyclomine—Nausea—Fludarabine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Dicyclomine—Shock—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Dicyclomine—Urticaria—Bleomycin—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Dicyclomine—Anorexia—Vincristine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Dicyclomine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Dicyclomine—Insomnia—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Dicyclomine—Paraesthesia—Carmustine—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Dicyclomine—Mood swings—Methotrexate—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Dicyclomine—Dyspnoea—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Dicyclomine—Somnolence—Carmustine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Dicyclomine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Dicyclomine—Decreased appetite—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Dicyclomine—Insomnia—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Dicyclomine—Paraesthesia—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Dicyclomine—Constipation—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Dicyclomine—Pain—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Dicyclomine—Breast disorder—Methotrexate—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Dicyclomine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Dicyclomine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Dicyclomine—Decreased appetite—Vincristine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Dicyclomine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Dicyclomine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Dicyclomine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Dicyclomine—Fatigue—Vincristine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Dicyclomine—Asthenia—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Dicyclomine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Dicyclomine—Constipation—Vincristine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Dicyclomine—Pain—Vincristine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Dicyclomine—Pruritus—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Dicyclomine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Dicyclomine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Dicyclomine—Pain—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Dicyclomine—Constipation—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Dicyclomine—Abdominal pain—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Dicyclomine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Dicyclomine—Abdominal pain—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Dicyclomine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Dicyclomine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Dicyclomine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Dicyclomine—Vomiting—Bleomycin—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Dicyclomine—Rash—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Dicyclomine—Dermatitis—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Dicyclomine—Asthenia—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Dicyclomine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Dicyclomine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Dicyclomine—Asthenia—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Dicyclomine—Nausea—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Dicyclomine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Dicyclomine—Dizziness—Carmustine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Dicyclomine—Vomiting—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Dicyclomine—Dizziness—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Dicyclomine—Rash—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Dermatitis—Carmustine—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Headache—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Dicyclomine—Vomiting—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Dicyclomine—Rash—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Dicyclomine—Dermatitis—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Dicyclomine—Headache—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Dicyclomine—Nausea—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Dicyclomine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Dicyclomine—Rash—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Dicyclomine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Dicyclomine—Headache—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Dicyclomine—Nausea—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Dicyclomine—Nausea—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Dicyclomine—Pain—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—lymphatic system cancer	0.000978	0.000978	CcSEcCtD
Dicyclomine—Rash—Methotrexate—lymphatic system cancer	0.00097	0.00097	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Dicyclomine—Headache—Methotrexate—lymphatic system cancer	0.000964	0.000964	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
